Literature DB >> 29771626

Effectiveness and impact of a single-dose vaccine against chickenpox in the community of Madrid between 2001 and 2015.

Pello Latasa1, Angel Gil de Miguel2, Maria Dolores Barranco Ordoñez3, Inmaculada Rodero Garduño1, Juan Carlos Sanz Moreno4, María Ordobás Gavín1, María Esteban Vasallo1, Macarena Garrido-Estepa5, Luis García-Comas1.   

Abstract

BACKGROUND: Chickenpox is a contagious airborne disease. Immunization by varicella vaccine is an effective preventive measure. The objective of this study is to evaluate the impact and effectiveness of a single-dose vaccination against chickenpox at 15 months of age.
METHODS: Observational study based on data from the Epidemiological Surveillance System of the Autonomous Community of Madrid from 2001 to 2015. The years were grouped into 4 periods according to epidemic cycles and vaccination schedule: 2001-06, 2007-10, 2011-13 and 2014-15. The impact was calculated as Relative Risk (RR) between the incidence of chickenpox in children between 15 months and 13 years of age between 2011-13 and 2001-06 through Poisson regression using notifications made to the Diseases of Compulsory Declaration (DCD) system, the Sentinel Physicians Network (SPN) and hospital discharge records noted as Minimum Basic Data Set (MBDS). The vaccine effectiveness (VE) was calculated using the screening method and a 1:2 case-control study paired by age and paediatrician in population from 15 months to 13 years and between 2007 and 2015 using SPN source data.
RESULTS: The RR2011-13/2001-06 using data from the DCD was 0.14 (95% CI: 0.14 to 0.15), 0.07 (95% CI: 0.06 to 0.08) from SPN and 0.17 (95% CI: 0.15 to 0.20) from MBDS. A total of 338 cases were included in the VE screening obtaining an overall of 76.7% (IC 95%: 71.9 to 80.7%). For a case-control study, 120 cases and 247 controls were recruited obtaining a VE of 92.4% (IC 95%: 80.8 to 97.0%).
CONCLUSIONS: The single-dose vaccination against chickenpox at 15 months of age has high impact and effectiveness.

Entities:  

Keywords:  Chickenpox; Epidemiological Monitoring; Sentinel Surveillance; Varicella vaccine

Mesh:

Substances:

Year:  2018        PMID: 29771626      PMCID: PMC6183198          DOI: 10.1080/21645515.2018.1475813

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  24 in total

Review 1.  Observational methods in epidemiologic assessment of vaccine effectiveness.

Authors:  Siranda Torvaldsen; Peter B McIntyre
Journal:  Commun Dis Intell Q Rep       Date:  2002

2.  The effectiveness of varicella vaccination in children in Germany: a case-control study.

Authors:  Johannes G Liese; Carine Cohen; Anita Rack; Kerstin Pirzer; Stefan Eber; Maxim Blum; Michael Greenberg; Andrea Streng
Journal:  Pediatr Infect Dis J       Date:  2013-09       Impact factor: 2.129

3.  Effectiveness of one and two doses of varicella vaccine in preventing laboratory-confirmed cases in children in Navarre, Spain.

Authors:  Manuel García Cenoz; Víctor Martínez-Artola; Marcela Guevara; Carmen Ezpeleta; Aurelio Barricarte; Jesús Castilla
Journal:  Hum Vaccin Immunother       Date:  2013-01-16       Impact factor: 3.452

4.  Epidemiology of varicella in Haidian district, Beijing, China-2007-2015.

Authors:  Jiye Fu; Chu Jiang; Juguang Wang; Fengxia Zhao; Tianwei Ma; Rujing Shi; Yanhong Zhao; Xianfeng Zhang
Journal:  Vaccine       Date:  2017-03-23       Impact factor: 3.641

5.  Preparing to introduce the varicella vaccine into the Italian immunisation programme: varicella-related hospitalisations in Tuscany, 2004-2012.

Authors:  Sara Boccalini; Paolo Bonanni; Angela Bechini
Journal:  Euro Surveill       Date:  2016-06-16

6.  Varicella-related Primary Health-care Visits, Hospitalizations and Mortality in Norway, 2008-2014.

Authors:  Grazina Mirinaviciute; Erle Kristensen; Britt Nakstad; Elmira Flem
Journal:  Pediatr Infect Dis J       Date:  2017-11       Impact factor: 2.129

7.  Safety profile of live varicella virus vaccine (Oka/Merck): five-year results of the European Varicella Zoster Virus Identification Program (EU VZVIP).

Authors:  Nicolas Goulleret; Elodie Mauvisseau; Mélanie Essevaz-Roulet; Mark Quinlivan; Judy Breuer
Journal:  Vaccine       Date:  2010-06-30       Impact factor: 3.641

8.  Postmarketing evaluation of the safety and effectiveness of varicella vaccine.

Authors:  S Black; H Shinefield; P Ray; E Lewis; J Hansen; J Schwalbe; P Coplan; R Sharrar; H Guess
Journal:  Pediatr Infect Dis J       Date:  1999-12       Impact factor: 2.129

9.  Effectiveness over time of varicella vaccine.

Authors:  Marietta Vázquez; Philip S LaRussa; Anne A Gershon; Linda M Niccolai; Catherine E Muehlenbein; Sharon P Steinberg; Eugene D Shapiro
Journal:  JAMA       Date:  2004-02-18       Impact factor: 56.272

10.  A sampling design for a sentinel general practitioner network.

Authors:  Napoleón Pérez-Farinós; Iñaki Galán; María Ordobás; Belén Zorrilla; José Luis Cantero; Rosa Ramírez
Journal:  Gac Sanit       Date:  2009-03-06       Impact factor: 2.139

View more
  2 in total

1.  Trends in varicella and herpes zoster epidemiology before and after the implementation of universal one-dose varicella vaccination over one decade in South Korea, 2003-2015.

Authors:  Jae-Ki Choi; Sun Hee Park; Sanghyun Park; Su-Mi Choi; Si-Hyun Kim; Dong-Gun Lee; Jin-Hong Yoo; Jung-Hyun Choi; Jin Han Kang
Journal:  Hum Vaccin Immunother       Date:  2019-05-07       Impact factor: 3.452

2.  Impact of varicella vaccination in Argentina: Seroprevalence in children and adults in a pediatric hospital.

Authors:  Angela Gentile; María Del Valle Juarez; María Florencia Lucion; María Natalia Pejito; Ana Clara Martínez; Agostina Folino; Mariana Viegas; Norberto Giglio
Journal:  Vaccine X       Date:  2021-12-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.